Manufacturer Janssen-Cilag is recalling batches of its doripenem powder due to the product license returning to its original holder.

All batches of Doribax (doripenem) 500mg, which are still in date and used as an infusion for treating infection, are being recalled, due to the license being returned to Shionogi & Co. Ltd.

There are no known quality or safety issues with the stock, the MHRA said on Monday (March 3).

Pharmacies can retain stocks of Doribax for patients who are currently prescribed the drug, the MHRA said. However, all stock should be returned once patients have completed their treatment, it added.

The drug is prescribed for hospital-acquired pneumonia, complicated intra-abdominal infections and complicated urinary-tract infections.

Enquiries regarding stock returns should be directed to Janssen-Cilag on 0800 731 5550, while medical information queries should be directed to 0800 731 8450.